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Immunoglobulins, antigens and complement can assemble to form immune com-
plexes (IC). ICs can be detrimental as they propagate inﬂammation in autoimmune
diseases. Like ICs, submicron extracellular vesicles termed microparticles (MP) are
present in the synovial ﬂuid from patients affected with autoimmune arthritis. We
examinedMPsinrheumatoidarthritis(RA)usinghighsensitivityﬂowcytometryand
electron microscopy. We ﬁnd that the MPs in RA synovial ﬂuid are highly hetero-
geneous in size. The observed larger MPs were in fact MP-containing ICs (mpICs)
and account for the majority of the detectable ICs. These mpICs frequently express
the integrin CD41, consistent with platelet origin. Despite expression of the Fc
receptor FcgRIIa by platelet-derived MPs, we ﬁnd that the mpICs form indepen-
dentlyofthisreceptor.Rather,mpICsdisplayautoantigensvimentinandﬁbrinogen,
andrecognitionofthesetargetsbyanti-citrullinatedpeptideantibodiescontributes
to the production of mpICs. Functionally, platelet mpICs are highly pro-inﬂamma-
tory, eliciting leukotriene production by neutrophils. Taken together, our data
suggest a unique role for platelet MPs as autoantigen-expressing elements capable
of perpetuating formation of inﬂammatory ICs.
INTRODUCTION
Upon activation, cells of many different lineages bud small
extracellular vesicles called microparticles (MP) (also known as
microvesicles or ectosomes) from the cytoplasmic membrane.
Given the universality of this process, MPs likely play essential
functions that include cell–cell communication and transporta-
tion of mediators (Beyer & Pisetsky, 2010; Distler et al, 2005b;
Gyorgy et al, 2011b).
It is increasingly appreciated that elevated levels of MPs are
evident in diverse diseases (Beyer & Pisetsky, 2010; Distler et al,
2005b; Gyorgy et al, 2011b). Platelet MPs in particular were
observed in autoimmune disorders including systemic lupus
erythematosus (SLE; Pereira et al, 2006; Sellam et al, 2009),
Sjo ¨gren’s syndrome (Sellam et al, 2009), multiple sclerosis
(Sheremata et al, 2008), antiphospholipid syndrome (Jy et al,
2007), and RA (Boilard et al, 2010, 2012; Knijff-Dutmer et al,
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capable of releasing MPs. Indeed, platelet MPs were the ﬁrst
type of MPs to be described originally designated as ‘‘platelet
dust’’ found abundantly in plasma (Chargaff & West, 1946;
Wolf, 1967).
Immune complexes (IC) represent immunoglobulins and
complement clustered about target antigen. They are extremely
potent at eliciting inﬂammatory responses and implicated in
response to infections as well as multiple autoimmune diseases
such as Sjo ¨gren’s syndrome (Voulgarelis & Tzioufas, 2010), SLE
(Munoz et al, 2010), multiple sclerosis (Cross et al, 2001;
Ziemssen&Ziemssen,2005),antiphospholipidsyndrome(Ruiz-
Irastorza et al, 2010) and RA (Nigrovic, 2006). Given the
simultaneous presence of ICs and MPs in autoimmune
disorders, we examined MPs keeping in mind that they could
themselvesserveasantigenicsurfaceforformationoffunctional
ICs, referred to hereafter as microparticle ICs (mpICs).
Usinghigh sensitivity ﬂowcytometry (hs-FCM),transmission
electron microscopy and proteomic approaches, we found that
ICsinRAsynovialﬂuidfrequentlyincludeMPs,therebyforming
true mpICs. Although we observed that MPs originating from
platelets express FcgRIIa, mpICs formed not through binding
to this receptor but rather by recognition of citrullinated
autoantigens such as vimentin and ﬁbrinogen. Together, these
results identify a unique site of autoantigen expression in RA
and suggest that MPs, including those derived from platelets,
may participate in the generation of a novel type of potent ICs in
this disease.
RESULTS
MPs in SF are highly heterogeneous in size
MPs are widely recognized as  100–1000nm extracellular
vesicles that can exhibit phosphatidylserine. These uncommon
features permit the detection of MPs cytoﬂuorometrically by
employing Annexin-V (which recognizes phosphatidylserine)
conjugated to ﬂuorochromes and size discrimination (Connor
et al, 2010; Gyorgy et al, 2011a; Perez-Pujol et al, 2007;
Thiagarajan & Tait, 1991). However, standard ﬂow cytometry is
not well adapted to the detection of such small MPs. The
demonstration of the common biophysical properties of ICs and
MPs (Gyorgy et al, 2011a) and the recent development of
improved ﬂow cytometry approaches for MP detection
prompted us to further analyse MPs in RA.
After optimizing high sensitivity ﬂow cytometry (hs-FCM)
parameters to distinguish small particles (Fig 1A), we assessed
sizeandquantityofMPsinRA.Forcomparison,theMPspresent
in psoriatic arthritis (PA) – a disease family not associated with
intra-articular ICs and complement consumption – were also
examined. Similarly to MPs, ICs can display dimensions ranging
from 100 to 1000nm (Gyorgy et al, 2011a). Further, since it is
hypothesized that ICs can interact with multiple MPs to form
larger components, we included all particles up to 3500nm in
diameter for our analyses. Interestingly, unlike MPs in PA SF,
MPs in RA SF appear highly heterogeneous in size and include
two major subpopulations, one exhibiting diameters ranging
from  100 to  300nm and a second one from  700 to
 3000nm (Fig 1B and C).
Given the common biophysical properties of ICs and MPs and
the prominent quantities of ICs in SF (Gyorgy et al, 2011a), we
utilized an established detergent lysis protocol to differentiate
these entities (Gyorgy et al, 2011a). With this method,
membrane phospholipids from MPs are solubilized by detergent
while the ICs remain intact (Gyorgy et al, 2011a). We observe
that theAnnexin-V
þparticles arepromptly solubilized by Triton
X-100 treatment, a ﬁnding consistent with the membrane
composition present in MPs (Fig 1D). These analyses reveal
745,000 171,000 Annexin-V
þ MPs/ml in SF of RA patients
(n¼23).Forcomparison,weﬁnd193,000 20,000Annexin-V
þ
MPs/ml in SF of PA patients (n¼18), signiﬁcantly lower than
the concentrations detected in RA (p¼0.0004; Fig 1E).
Interestingly, we observe that MPs in RA SF are not only more
abundant than in PA SF, they also display different dimensions,
suggesting that they are associated with other macromolecular
structures.
MPs and ICs associate in SF from patients with RA, not PA
Intrigued by the presence of large dimension MPs in RA SF, we
hypothesized that MPs could bind immunoglobulins and
thereby form large MP-containing ICs (mpICs). To assess the
presence of mpICs in RA SF, we used cryo-TEM, which allows
direct visualization of small particles and their membrane
bilayers. We further examined the exposure of phosphatidyl-
serine in RA SF mpICs using Annexin-V conjugated to 4nm
gold nanoparticles and identiﬁed immunoglobulin containing
ICs using larger gold nanoparticles (10nm) conjugated to
protein A. Using this method, we identify macromolecular
structures up to 2mm in diameter that contain both ICs and MPs
(mpICs). Interestingly, these mpICs often harbour multiple MPs
at the periphery (Fig 2A–C),  65% of them expressing
phosphatidylserine. Importantly, these observations were
veriﬁed in freshly obtained RA SF (n¼5), ruling out the
involvement of freezing–thawing in an artifactual generation
of mpICs.
Having visualized mpICs, we employed hs-FCM to analyse
them (Fig 3A). We measure 39,400 9400mpICs/mli nR AS F
(Fig 3B). The quantiﬁcation of the ICs in these same ﬂuids
(Supporting Information Fig S1) reveals that the majority
(62 7%) of the detectable ICs are in fact mpICs (Fig 3C). These
observations provide an explanation for the presence of two
subpopulations of MPs evident in RA SF. Speciﬁcally larger
particles (from  700 to 3000nm; upper inset in Fig 3A) contain
mpICs. Conversely, the MPs not associated with IgG are
characterized by smaller dimensions (100–300nm; lower inset
in Fig 3A) and represent the majority of the total Annexin-V
þ
MPs (93% 1.4; Supporting Information Fig S2). Interestingly,
although MPs and IgG are both present in PA SF, only
2000 900mpICs/ml could be detected (Fig 3B and D).
Platelet-derived mpICs are present in RA SF
Having established the presence of mpICs in RA SF, we next
investigated mechanisms by which ICs and MPs combine. A key
question forfurthermechanistic investigation isidentiﬁcationof
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236  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 235–249the cellular source(s) of MPs in SF. Considering their role in
arthritis (Boilard et al, 2010, 2012), we queried whether platelet
MPs contribute signiﬁcantly to mpICs in RA SF. For these
analyses, we assessed the presence of the platelet speciﬁc
integrin CD41 in mpICs using hs-FCM. Consistent with the vast
heterogeneity that prevails among RA patients, the amount of
CD41
þ mpICs in RA SF differs from one patient to another
(n¼25; two examples shown on Fig 3E). Interestingly,
the number of CD41
þ mpICs in RA SF is signiﬁcantly higher
than those observed in PA SF (n¼18; p¼0.0006; Fig 3F).
Importantly, although the ICs remain intact after detergent
treatment, the CD41
þ MPs contained in mpICs are detergent
soluble, further establishing their phospholipid composition
(Fig 3G).
Platelet mpICs form independently of FcgRIIA
Humanplateletsexpressthe ICreceptorFcgRIIA(CD32a;Huang
et al, 2011; Parren et al, 1992). We thus postulated that CD32a
present on platelet-derived MPs may contribute to formation
of mpICs. In this set of experiments, we initially assessed
CD32a expression by platelet-derived MPs. Since platelets
promptly release MPs following stimulation of the collagen
receptor glycoprotein VI (GPVI) (Boilard et al, 2010; Knight
et al, 1999), and since GPVI deﬁciency in mice leads to
reduction of the severity of arthritis (Boilard et al, 2010),
we generated MPs via this arthritis-relevant stimulus. Here, we
ﬁnd that platelet-derived MPs retain CD32a (Fig 4A). Examina-
tion of MPs in RA SF demonstrates they too harbour CD32a
(Fig 4B).
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Figure 1. MPs are heterogeneous in size and are more abundant in RA compared to PA SF.
A. Acquisition of fluorescent Sky Blue microspheres of 40–90nm (mean¼90nm, in cyan blue), 100–300nm (mean¼220nm, in pink), 400–600nm
(mean¼450nm, in green), 700–900nm (mean¼840nm, in blue), 2500–4500nm (mean¼3200nm, in violet) diameter on a flow cytometer Canto II
modifiedwithaFSC-PMTsmallparticlesoption.Ascale barranging from100to 3200nm basedonthemicrosphere sizes(FSC-PMT)ispresentedand usedto
determine the relative dimensions of the MPs.
B,C. Representative FSC-PMT and SSC portrayals of the Annexin-V
þ events detected in RA SF (B) and PA SF (C) revealing the dimension diversity of the MPs. The
relativedimensionsoftheMPs arepresented accordingtosize-definedmicrospherecalibrations.Twomajorsubpopulations(subpop1and2)aredetectedin
RA SF (B) while only one (subpop 1) is observed in PA SF (C) are identified on the graphs.
D. Triton sensitivity of the MPs in RA SF detected using Annexin-V labeling presented as % of untreated (control).
E. Flow cytometric quantifications of the Annexin-V
þ MPs contained in RA and PA SF (n¼23 RA and n¼18 PA
   p¼0.0004). Statistical analyses are presented
under the graph. Data are mean SEM.
EMBO Mol Med (2013) 5, 235–249  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 237To assess a contribution of platelet MP CD32a in mpIC
formation, we incubated in vitro generated platelet MPs in the
presence of RA SF (n¼10) or PA SF (n¼18). In this assay, the
ﬂuorescent label present in in vitro MPs affords discrimination
of newly formed mpICs from those present endogenously. As
anticipated, the ﬂuorescent platelet MPs are easily detected by
hs-FCM, are smaller than intact platelets, the vast majority of
them having dimensions of  100–300nm in diameter (Fig 4C).
Strikingly, the incubation of ﬂuorescent platelet MPs in RA SF
yields two subpopulations (Fig 4D), including the larger
dimension (700–3000nm) subpopulation that contains mpICs
(Fig 4E). Interestingly, this subpopulation does not form when
the platelet MPs are exposed to PA SF (Fig 4D, F and G). To
explore the contribution of CD32a in formation of mpICs in RA
SF, we pre-incubated the platelet MPs with a blocking CD32a
antibody. We ﬁnd that blockade of CD32a does not impede
formation of mpIC (Fig 4G; n¼10, p¼0.4478).
Role of citrullination in generation of mpICs
Autoantibody/antigen binding comprises another plausible
mechanism for formation of mpIC. Among the mechanisms
that occur in RA SF and not in PA SF is citrullination, a process
that generates neoepitopes recognized by autoantibodies
present in abundance in many patients with RA (Yoshida
et al, 2006). Speciﬁcally, citrullination is a posttranslational
modiﬁcation of peptidyl-arginine to peptidyl-citrulline by
peptidyl arginine deiminase (PAD) enzymes; in RA SF, the
PAD4 isoform levels are signiﬁcantly elevated (Arita et al, 2004;
Lundberg et al, 2005). Given that MPs are present in a milieu
where citrullination is active, we hypothesized that the MP
surface proteins may become citrullinated and give rise to
autoantigens recognized by autoantibodies in RA patients
and thereby promote mpIC formation. Using hs-FCM, we ﬁrst
evaluated whether platelet MPs are citrullinated in the course of
RA pathogenesis. We ﬁnd that, unlike platelet MPs generated
in vitro and those in PA SF, the platelet MPs in RA SF contain
citrullinated epitopes (Fig 5A and B), pointing to citrullination
of MPs as a potential mechanism leading to recognition by
autoantibodies.
To evaluate the contribution of citrullination on MPs to
recognition by autoantibodies in RA SF, we incubated platelet
MPsinpresenceofpuriﬁedPAD4andassessedtheirantigenicity
to IgG from RA SF. Interestingly, we ﬁnd that multiple
citrullinated proteins in platelet MPs are recognized by
autoantibodies from RA patients (6 RA patients out of 12; 2
patients represented in Fig 5C). For comparison, we evaluated
whether antibodies from PA could recognize citrullinated
proteins from platelet MPs. We demonstrate that citrullination
Research Article www.embomolmed.org
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Figure 2. Visualization of the mpICs in RA SF. Cryo-TEM detection of immunoglobulins and phosphatidylserine exposing MPs using, respectively protein
A-conjugated gold nanoparticles (10nm) and Annexin-V-conjugated gold nanoparticles (4nm).
A,B. Representative observations obtained using RA SF in which MPs [white boxes labelled MP (MP 1 and MP 2 (A) and MP (B)] were colocalized with  2mm
diameter mpICs. White arrows indicate the edge of the IC where MPs were detected. Black arrows indicate the carbon matrix of the perforated support film
used for TEM. Insets (bottom panels) include individual MPs. Immunoglobulins detected using protein A conjugated nanospheres (10nm) are indicated
with white arrowheads and MPs detected using Annexin-V conjugated nanospheres (4nm) are indicated by black arrowheads. Note that some MPs were
Annexin-V negative.
C. Relatively smaller mpICs were also visualized. White and black arrowheads indicate immunoglobulins and phosphatidylserine, respectively. Scale bars are
presented under each panel.
238  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 235–249of MPs does not increase binding of antibodies from SF of PA
patients (0 PA patient out of 8 tested; 2 patients represented in
Fig 5D), consistent with the minimal presence of mpICs in this
disease (Fig 3B and F).
Identification of the autoantibodies derived from mpICs
Proteomic analyses permit the identiﬁcation of the antigens
targeted by autoantibodies (Hueber et al, 2005; Monach et al,
2009; Zhao et al, 2008). To identify autoantigens expressed
by platelet MPs, we isolated the CD41
þ mpICs from RA SF
using magnetic afﬁnity columns. These CD41
þ-enriched pre-
parations, composed of immunoglobulins and complement
C3a (466.6 193pg C3a/mg protein, n¼23), were applied to
protein G afﬁnity columns and the IgG within mpICs were
isolated. Using an autoantigen microarray (Hueber et al, 2005;
Robinson et al, 2002), we demonstrate that the IgG from platelet
mpICs associate with a broad series of recognized citrullinated
autoantigens (Fig 6A).
MPs exhibit autoantigens
Having identiﬁed the autoantibodies in platelet mpICs, we next
usedmassspectrometrytodeterminewhetherplateletmpICsalso
include autoantigens. We demonstrate that several canonical RA
autoantigens are present in platelet mpICs (Table 1). Among
these autoantigens present in platelet mpICs and recognized by
the IgG eluted from platelet mpICs, we focused our attention
www.embomolmed.org Research Article
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Figure 3. MPs, including platelet MPs, in RA SF form mpICs.
A. FSC-PMTandSSCdotplotsofrepresentativeRASFlabelledwithacombinationofFITC-conjugatedAnnexin-VandCy5-conjugatedanti-IgGtodemonstratethe
presence of IgG on surface of Annexin-V
þ MPs. The four-quadrant gates were positioned according to the isotypic controls. The MPs (Annexin-V
þ-IgG
 ) in blue
show dimensions ranging mostly from 100 to 300nm (lower inset) while the mpICs (Annexin-V
þ-IgG
þ) in green have dimensions from 700 to 3000nm (upper
inset). The relative diameters are presented according to size-defined microsphere calibrations.
B. Quantifications of the mpICs contained in RA and PA SF (n¼23 RA and n¼18 PA
   p<0.0001).
C. Quantifications of the mpICs relative to the total amounts of detectable ICs in RA SF (n¼23). The statistical analyses are presented under each graph. Data are
mean SEM.
D. FSC-PMT and SSC dot plots of representative PA SF labelled with a combination of FITC-conjugated Annexin-V and Cy5-conjugated anti-IgG.
E. FSC-PMT and SSC dot plots of RA SF patients labelled with PE-conjugated anti-CD41 and Cy5-conjugated anti-IgG. The four-quadrant gates were positioned
according to the isotypic controls. The presence of CD41
þ mpICs is evidenced by the dual expression of CD41 and IgG by MPs (green region). RA SF from two
patients are presented to illustrate the heterogeneity that exists among the patients.
F. Quantifications of the CD41
þ mpICs in RA and PA SF (n¼25 RA and n¼18 PA
   p¼0.0006). The statistical analyses are presented under each graph. Data are
mean SEM.
G. Triton sensitivity of the CD41
þ mpICs contained in RA SF presented as % of untreated (control) CD41
þ mpICs.
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Figure 4. Platelet MPs form mpICs independently of CD32a.
A,B. The expression of CD32a by platelet MPs was determined by hs-FCM and Western blot analysis (inset in A). The platelet MPs were generated in vitro upon
platelet GPVI stimulation (A) and the endogenous MPs in RA SF were detected using Annexin-V (B). Blue: isotype; grey: specific CD32a labeling (n¼3).
C. FSC-PMT and SSC profiles of the fluorescent platelets (top panel) and platelet MPs (bottom panel) (n¼10). The relativedimensions are presented according
to size-defined microsphere calibrations.
D–G. Resultsobtained following theincubationof exogenous fluorescent platelet MPs in RA and PA SF(n¼10 RA andn¼18 PA).(D)Representative FSC-PMT and
SSC plots obtained using RA (top) and PA SF (bottom). Two subpopulations (subpop) (1 and 2) were detected in RA and only one in PA SF (1). (E,F) hs-FCM
evaluationofthepresenceofIgGonsurfaceofMPsuponincubationinRA(E)andPASF(F)usingCy5-conjugatedanti-IgG antibody.Thefour-quadrantgates
were positioned according to the isotypic controls. (E) MPs (in green) are IgG
  and show dimensions ranging from 100 to 300nm (lower inset) while the
mpICs (in blue) have dimensions ranging from 700 to 3000nm (upper inset). (D,E) The relative dimensions are presented according to size-defined
microsphere calibrations. (G) hs-FCM quantifications of the mpICs were determined in absence (1st and 3rd column) or presence (2nd column) of CD32a
blockingantibody (1stand 2nd column p¼0.4478 (unpaired t-test), 1st and 3rd column
   p<0.0001). Statisticalanalyses are presented underthegraphs.
Data are mean SEM.
240  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2013) 5, 235–249on the two previously described autoantigens vimentin (El-
Gabalawy & Wilkins, 2004; Kurki et al, 1983) and ﬁbrinogen
(Takizawa et al, 2006). Vimentin is an intracellular cytoskeleton
protein expressed on the surface of platelet-derived MPs (Podor
et al, 2002) and autoantibodies directed against citrullinated-
vimentin are present in RA SF (El-Gabalawy & Wilkins, 2004;
Kurki et al, 1983). We thus examined the expression of vimentin
onsurface ofin vitrogenerated platelet-derived MPs andplatelet
MPs contained in RA SF. We ﬁnd that the surface of both in vitro
generated platelet MPs and those isolated from RA SF exhibit
signiﬁcant expression of vimentin (Fig 6B).
Fibrinogen is also a known autoantigen in RA and
autoantibodies directed against citrullinated ﬁbrinogen sufﬁce
to induce arthritis in mice (Ho et al, 2010). While ﬁbrinogen is a
ligand of the platelet integrins GPIIb/IIIa (Bodary et al, 1989),
we conﬁrmed that ﬁbrinogen interacts with platelet MPs.
We therefore examined the ability of platelet MPs to associate
with ﬂuorescent ﬁbrinogen using hs-FCM. Interestingly,
exogenous ﬁbrinogen promptly binds to platelet MPs obtained
in vitro and to platelet MPs from RA SF, demonstrating that MPs
of platelet origin associate with the autoantigen (Fig 6C).
Fibrinogen is expressed in the platelet’s alpha granules
www.embomolmed.org Research Article
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Figure 5. Platelet MPs display citrullinated autoantigens recognized by IgG from RA SF.
A,B The presence of citrullinated epitopes on platelet MPs was determined by hs-FCM using anti-citrulline antibody and its corresponding secondary antibody
conjugated to Alexa 647. MPs were confirmed of platelet origin using a PE-conjugated anti-CD41 antibody. (A) The presence of citrullinated antigens on
platelet MPs was determined in in vitro platelet MPs (left panel) and MPs from RA SF (right panel). The vertical lines were positioned according to the isotypic
controls. Pink: Negative population; blue: Positive population. The % of positive platelet MPs is indicated on graphs. (B) Quantification of the citrulline
þ
CD41
þ MPs in RA and PA SF (n¼8 RA and n¼8P A
 p¼0.0148).
C,D The proteins from platelet MPs obtained in vitro left unmodified ( PAD4) or citrullinated (þPAD4) were separated on SDS–PAGE and transferred to
membranes. The membranes were incubated in presence of RA (C)o rP A( D) SF and the recognition of MP-derived autoantigens by autoantibodies from SF
was revealed using HRP-conjugated anti-human IgG. Arrows indicate proteins recognized by IgG from SF uniquely when the MPs were citrullinated. Two RA
and PA SF are presented to illustrate the existing variability between patients (n¼12 RA and n¼8 PA).
EMBO Mol Med (2013) 5, 235–249  2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 241(Sehgal & Storrie, 2007), is present in RA SF (Takizawa
et al, 2006) as well as being an abundant plasma protein. We
thus evaluated whether platelet MPs interacted with endoge-
nous ﬁbrinogen in vitro and ex vivo. Interestingly, we
demonstrate that, similar to platelet MPs produced in vitro,
platelet MPs present in RA SF exhibit surface ﬁbrinogen
(Fig 6D). Together, these data show that platelet MPs are
capable of displaying autoantigens vimentin and ﬁbrinogen
which, when citrullinated, could allow binding by autoanti-
bodies in RA SF.
Platelet mpICs are pro-inflammatory
TheinﬂammatorylipidmediatorsleukotrienesarepresentinRA
synovial ﬂuid (Klickstein et al, 1980) and its production by
neutrophils, a cellular lineage dominant in the synovial ﬂuid
from RA patients (Edwards & Hallett, 1997), contribute to the
pathophysiologyofinﬂammatoryarthritisininvivomechanistic
models (Chen et al, 2006). Similarly to MPs, the mpICs can be
centrifuged and used as cellular stimulus. We thus centrifuged
SF from RA patients and used the resulting pellet to determine
its potency on human neutrophils. We demonstrate that this
fraction, which contains both MPs and mpICs, can stimulate
neutrophils to produce leukotrienes (Fig 7A). We next used
in vitro generated mpICs to examine whether they could elicit
the release of leukotrienes from neutrophils. We ﬁnd that
mpICs, which spontaneously form after the co-incubation of
platelet MPs with anti-ﬁbrinogen (Fig 7B), induce robust
leukotrieneproductionbyneutrophils(Fig7C).Forcomparison,
platelet MPs and anti-ﬁbrinogen are only modestly active when
added to neutrophils separately (Fig 7C). To assess the relative
pro-inﬂammatory activity of mpICs, we fractionated mpICs,
MPs and anti-ﬁbrinogen ICs via size exclusion ﬁltration (800nm
pores). Interestingly, we show that the mpIC depletion
abrogates much of the leukotriene stimulation in this assay
(Fig 7C), establishing that the platelet mpICs are active and
highly pro-inﬂammatory.
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Figure 6. Platelet MPs in RA SF exhibit
autoantigens.
A. Identification of the autoantibodies contained
in CD41
þ mpICs in RA SF. The binding speci-
ficity of the mpIC-eluted IgG to 40 antigens
was determined on a Bio-Plex
TM bead-based
antigen array and only the antigens that
presented significant binding are presented
(n¼23 RA patients, identified 1–23). Colours
denote amount of binding: undetectable
(blue); progressively greater binding (green,
yellow, red). Color scale is presented on right.
The negative control (C) was obtained by
incubating isotypic antibodies in SF. Cfc; cyclic
citrullinated filaggrin, H2A/a; histone H2A/a.
B–D. The presence of autoantigens was examined
on in vitro platelet MPs (left) and platelet MPs
from RA SF (right) by hs-FCM (n¼4). (B) MPs
were incubated with anti-vimentin and the
interaction was revealed using Alexa 647-
conjugated secondary antibody. (C) MPs were
incubated with exogenous Alexa 647-fluor-
escent fibrinogen and associations quantified
by hs-FCM. (D) MPs were incubated with anti-
fibrinogen and the interaction with endoge-
nous fibrinogen was determined using Alexa
647-conjugated secondary antibody. The ver-
tical lines were positioned according to the
isotypic controls. Green: negative population;
blue: positive population. The % of positive
MPs is indicated on graphs.
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Our work identiﬁes a highly pro-inﬂammatory macromolecular
structure composed ofMPs and immune complexes abundantin
RA synovial ﬂuid. Further, our mechanistic studies show that
MPs, including platelet MPs, in RA SF are not naked
phospholipid vesicles. Rather, they express or associate with
autoantigens, can be citrullinated and form bioactive inﬂam-
matory mpICs.
The identiﬁcation of MPs as a site of autoantigen expression
extendspreviousseminalobservationsregardingMPsandICsin
RA synovial ﬂuid. Others had suggested that complement and
immunoglobulins were associated with the substantial majority
of MPs in RA SF (Biro et al, 2007). However, no membrane
markers such as Annexin-V, or lineage markers such as CD41,
were utilized to distinguish MPs from ICs in those standard ﬂow
cytometry experiments. More recent demonstration of common
biophysical properties (size, light scattering, sedimentation)
between ICs and MPs has called into question whether or not
MPs and immunoglobulins are associated in RA SF and
demonstrate the need for using lineage markers or other
methods to further clarify the interpretation of previous
observations (Gyorgy et al, 2011a). Our ﬁndings reﬁne and
unify these discrepant observations by demonstrating that
although only a proportion ( 7%) of the MPs are part of mpICs,
the majority of the detectable ICs are in fact mpICs.
The presence of immunoglobulins on surface of MPs in blood
during RA has been previously examined (Nielsen et al, 2012;
van Eijk et al, 2010). In contrast to our demonstration of MP
interactions with ICs in RA SF, those studies did not ﬁnd
evidenceofMPassociationwithICsinRAblood.Althoughthese
observations may point to the existence of highly potent
vascular and reticular-endothelial system clearance mecha-
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Figure 7. Platelet mpICs promote leukotriene
production by neutrophils.
A. Quantifications of the leukotriene biosynthesis by
neutrophils incubated in presence of RA SF mpICs
[n¼3 distinct patients
   p<0.0001 patients 1
and 2;
  p¼0.0011 patient 3 (unpaired t-test,
relative to PBS control)]. Data are mean SEM.
Leukotrienes measured represent the sum of
LTB4, 6-trans-LTB4, 12-epi-6-trans-LTB4, 20-OH-
LTB4 and 20-COOH-LTB4.
B. Platelet mpICs form promptly uponco-incubation
of platelet MPs with anti-fibrinogen in vitro.
Representative FSC-PMT and SSC dot plot of
mpICs. The presence of mpICs formed in vitro was
demonstrated using a combination of FITC-con-
jugated Annexin-V and Alexa 647-conjugated
secondary antibody. The four-quadrant gates
were positioned according to the isotypic con-
trols. The MPs (Annexin-V
þ-IgG
 ) presented in
blue show dimensions ranging mostly from 100
to 500nm (lower inset) while the mpICs
(Annexin-V
þ-IgG
þ) presented in purple display
dimensions ranging from 800 to 3000nm
(upper inset). The relative dimensions are pre-
sented according to size-defined microsphere
calibrations.
C. Quantifications of the leukotriene biosynthesis by
neutrophils incubated in presence of in vitro
mpICs, anti-fibrinogen and platelet MPs. The
stimulatory potency of mpICs compared to the
others conditions was statistically significant
[n¼3
   p 0.0001 (unpaired t-test)]. Data are
mean SEM. Leukotrienes measured represent
the sum of LTB4, 6-trans-LTB4, 12-epi-6-trans-
LTB4, 20-OH-LTB4 and 20-COOH-LTB4.
Table 1. Identification of the autoantigens included in CD41
þ MPs from
RA SF
Protein ID Number of peptides
a
Apolipoprotein A-1 7; 8; 4; 5
Clusterin 0; 2; 0; 0
Fibrinogen alpha chain 6; 16; 14; 11
Fibrinogen beta chain 0; 13; 15; 6
Histone H2A 2; 3; 3; 3
Histone H2B 2; 4; 2; 4
Vimentin 0; 1; 0; 2
aThe number of peptides detected for each protein is indicated for each RA
patient.
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the inﬂamed joint. Indeed, the MPs derived by platelets in blood
during RA (Knijff-Dutmer et al, 2002; Sellam et al, 2009) may
accumulate in the SF through the gaps present between the
endothelial cells in the inﬂamed vasculature (Boilard et al, 2012;
Cloutier et al, 2012). Once in SF (where PAD4 is present), MPs
mayundergocitrullinationandformmpICs.Theexactanatomical
site where mpICs form and the mechanism(s) of transportation of
mpICs remains the subject of intense investigation.
Although the detection of phosphatidylserine is commonly
used to determine the presence of MPs, Annexin-V
  MPs are
also observed in substantial numbers associated with ICs.
Nevertheless, all the mpICs we examined by cryo-TEM were
composed of at least one Annexin-V
þ MP, suggesting that
quantiﬁcations of mpICs based on Annexin-V detection still
remain reasonably accurate. Although little is known about the
origin of these Annexin-V
  MPs, they are also abundant in
plasma (Connor et al, 2010) and may originate from distinct
stimuli. Indeed, platelet activation via collagen or thrombin
producesAnnexin-V
 MPs(Connoretal,2010;Perez-Pujoletal,
2007). Their presence provides evidence for further signiﬁcant
diversity of MPs in RA SF.
While platelet-derived MPs do express CD32a, its contribu-
tiontoformationofmpICsisquantitativelymodest.Ontheother
hand, we show that platelet MPs can interact with autoanti-
bodies against citrullinated antigens via at least two mechan-
isms, (i) following the citrullination of its surface and (ii) upon
binding to citrullinated proteins. Autoantigens other than
vimentin and ﬁbrinogen may also be expressed on surface of
platelet MPs during RA. Indeed, multiple citrullinated proteins
derived from PAD4-treated MPs are recognized by RA auto-
antibodies. Further, we also identify autoantibodies against
canonical citrullinated RA autoantigens such as ﬁlaggrin
(including cfc), enolase and histone H2A/a in mpICs. Among
these other proteins, only histones were also identiﬁed in our
mass spectrometry analyses. Histones may be associated with
DNA,itselfboundtoMPs.Alternatively,histonesarerecognized
potent platelet stimuli and can associate with platelets directly
(Fuchsetal,2011).PlateletMPs,likeplatelets,maythusinteract
with histones and could be recognized by anti-histone
autoantibodies. Although the contribution of these autoantigens
to mpIC formation remains to be identiﬁed, we establish that
major autoantigens in RA are exposed on the surface of platelet-
derived MPs.
Other types of extracellular vesicles may express auto-
antigens. Small apoptotic CD3
þ T cells, for instance, expose
vimentin (Boilard et al, 2003) and could potentially interact
with anti-vimentin autoantibodies if present in RA SF.
Furthermore, exosomes, vesicles derived from intracellular
compartments, also display antigens in RA SF (Skriner et al,
2006). MPs from other cellular origins (other than platelet-
derived) may also express autoantigens. Considering that MPs
from multiple sources populate the SF (Berckmans et al, 2002;
Boilard et al, 2010), it is highly plausible that they too form
mpICs. We revealed the capability of PAD4 to use platelet MPs
as substrate. This process is likely to occur on other MPs,
regardless of their origin, promoting the formation of additional
citrullinated autoantigens in RA SF. However their identity and
contribution remain to be established.
Recognizing the pro-inﬂammatory functions of MPs (Berck-
mans et al, 2005; Boilard et al, 2010; Distler & Distler, 2010;
Distler et al, 2005a; Messer et al, 2009; Reich et al, 2011) and IC
(Ho et al, 2010; Korganow et al, 1999; Kuhn et al, 2006; Stuart &
Dixon, 1983) when taken separately, our identiﬁcation of mpICs
insynovialﬂuid uncovers a previously unappreciated physiology
of potential relevance both to host defense and to autoimmune
disease. During infections, ICs can efﬁciently trigger the
opsonization and the clearance of pathogens. Platelets are highly
potent producers of MPs and there is a growing appreciation of
the roleofplatelets inimmunity(Boilard etal, 2012; Semple etal,
2011). Although the recognition of bacterial products by platelets
can initiate the production of MPs (Brown & McIntyre, 2011),
whether the formation of inﬂammatory mpICs can occur in a
physiologically beneﬁcial manner in the course of the responses
against pathogens is unknown.
In the context of autoimmunity, we show that platelet MPs
can support immunoglobulin deposition. Since platelet MPs are
abundant in autoimmune diseases (Berckmans et al, 2005;
Boilard et al, 2010; Distler & Distler, 2010; Distler et al, 2005a;
Messer et al, 2009; Reich et al, 2011), they may be a crucial
source of autoantigens for the constant autoantibody deposition
that perpetuates inﬂammation in chronic disorders. We further
demonstrate that platelet mpICs are highly potent in promoting
the production of leukotrienes by neutrophils. In addition to
their capability to activate leukocytes, mpICs may harbour
unique roles, not played by conventional ICs. Although we do
not exclude that MPs also nucleate ICs, our analyses permitted
us to visualize MPs at the periphery of the ICs. An inﬂammatory
mpIC may thus interact with different cell types or may be
directed to speciﬁc locations via the adhesion molecules present
on the MPs that populate its surface. Further, we speculate that
the formation of mpICs contributes to disease pathophysiology
in other disorders. ICs are also present in multiple inﬂammatory
autoimmune disorders and are reported to propagate disease
(Cross et al, 2001; Ho et al, 2010; Korganow et al, 1999; Kuhn
et al, 2006; Monach et al, 2009; Munoz et al, 2010; Ruiz-
Irastorza et al, 2010; Stuart & Dixon, 1983; Voulgarelis &
Tzioufas, 2010; Zhao et al, 2008; Ziemssen & Ziemssen, 2005).
Indeed, circulating MPs in SLE patients are associated with
autoantibodies and complement (Nielsen et al, 2012; Ullal et al,
2011). In sum, the mechanism behind the creation of functional
mpICs, presented here, may well apply to other biological
contexts.
In conclusion, we report that in RA, platelet MPs exhibit
antigens that are recognized by RA speciﬁc autoantibodies. ICs
are commonly described as immunoglobulins-, antigens- and
complement-containing structures. We clearly establish that ICs
can also contain MPs, including platelet MPs, and form pro-
inﬂammatory mpICs. These observations extend previous
deﬁnitions about the nature of ICs and expand our insights
into the contributions of MPs and ICs to disease physiology in
RA.Consideringtherapidlyemergingfunctionsofinﬂammatory
MPs,ourﬁndingspointtopotentialrolesindiverseautoimmune
diseases characterized by presence of autoantibodies and MPs.
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Collection and preparation of synovial fluids
Human knee SFs as discarded material from patients with various
arthritides undergoing diagnostic by the treating attending rheuma-
tologist or therapeutic arthrocentesis. All studies received Institutional
Review Board approval (BWH). Fresh SF harvested without anti-
coagulant were cleared of leukocytes by centrifugation at 1900g for
30min at 48C, were aliquoted and were kept at  808C.
Platelet MP production and isolation
Platelets were obtained from citrated blood of healthy human
volunteers under an approved Institutional Review Board protocol
(CRCHUQ, Universite ´ Laval). Platelets were isolated (Boilard et al,
2011), resuspended at 100 10
6/ml in Tyrode’s buffer and stimulated
using 0.5mg/ml cross-linked collagen related peptide (Kehrel et al,
1998) for 120min at RT. The activation reaction was stopped by
addition of 20mM EDTA. The preparation was centrifuged at 1300g
for 5min twice, then at 18,000g for 90min at 188C and the pellet
containing the MPs was resuspended in Tyrode’s buffer. When
fluorescent MPs were required, platelets were incubated in presence
of 5mM Cell Tracker CMFDA (5-chloromethylfluorescein diacetate,
Invitrogen, ON, Canada) for 15min prior to stimulation.
Flow cytometry analyses of MPs and pre-analytical steps
MPs contained in SF were not pelleted before labelling to ensure that
most of the MPs we analysed (Lacroix et al, 2012). MPs were not
filtered to ensure we analysed the larger mpICs. All of the buffers were
filtered on 0.2mm pore size membranes (Fisher Scientific, ON,
Canada). A forward scatter (FSC) coupled to a photomultiplier
tube (PMT) ‘small particles option’ (FSC-PMT) (rather than the
usual diode; van der Vlist et al, 2012) with a 488nm solid state,
100mW output blue laser (rather than the conventional 20mW), a
633nm HeNe, 20mW output red laser and a 405nm solid state
diode, 50mW output violet laser were mounted on the FACS
Canto II Special Order Research Product used for all our studies
(BD Biosciences, ON, Canada). The chosen parameters were optimal to
detect particles from 100 to 3500nm simultaneously on the FSC-PMT.
In all experiments, the sensitivity and specificity of the MP labelling
were rendered optimal by using fluorochromes excited by three
distinct lasers.
MP and IC labelling
SF (10ml) were incubated with 0.5mg of Cy5-conjugated F(ab0)2 goat
anti-human IgG (anti-IgG-Cy5) (Jackson ImmunoResearch, PA, USA)
and 0.5mg of PE-conjugated mouse anti-human CD41 (M148) (anti-
CD41-PE) (Abcam, MA, USA) in combination to 5ml of FITC or V450-
conjugated Annexin-V (BD). The samples were labelled during 30min
in a volume of 100ml of Annexin-V buffer 1  and diluted to 600ml
before hs-FCM analysis. To process the data quantitatively, 100,000
polystyrene microsphere (15mm diameter; Polysciences, PA, USA) were
added to each tube and 1000 microspheres were acquired. The
included Annexin-V
þ or CD41
þ events were portrayed as FSC-PMT
versus side scatter (SSC) graph and the relative dimensions were
displayed according to the acquisition of Sky Blue microspheres of
mean diameter of 90, 220, 450, 840 and 3200nm (Spherotech, IL,
USA). The sensitivity of the MPs to detergent was assessed by addition
of Triton X-100 to the SF samples (1:5 in PBS) prior to addition of the
antibodies (Gyorgy et al, 2011a).
IgG–MP interaction
Fluorescent MPs (20 10
6) were incubated in presence of 50mlR Ao r
PA SF in final volume 100ml PBS for 48h at 48C. Then, 50mlo ft h e
cocktail were incubated with anti-IgG-Cy5 as described above. When
the contribution of CD32a was evaluated, 20mg/ml of CD32a blocking
Fab fragment antibody (clone IV.3, gift from Dr Paul Naccache,
Universite ´ Laval) was added 15min prior to MP addition to SF.
Western blotting
Platelets and MPs were prepared as described above, lysed and the
protein content was determined using the Pierce BCA protein assay kit
(Fisher Scientific). One microgram of sample was lysed in Laemmli
buffer, electrophoresed, transferred onto membranes and incubated in
0.2% milk/TBS-Tween solution containing a serum raised against a
peptide in the cytoplasmic domain of CD32a (CT10; Ibarrola et al,
1997).The membrane was washed, treated with Peroxidase-AffiniPure
anti-rabbit-IgG (Jackson ImmunoResearch) and reactive proteins were
visualized by chemiluminescence (Perkin Elmer, MA, USA).
Evaluation of presence of antigens on MP surface
Fluorescent platelet MPs (5 10
6)o rR AS F( 5 ml pre-incubated
with Annexin-V-V450) were incubated with 2ml of PE-conjugated
anti-human CD32 (clone IV.3) (Beckman Coulter, ON, Canada). To
determine the capability of MPs to associate with exogenous
fibrinogen, 15mg/ml of Alexa Fluor-647-conjugated fibrinogen
(Invitrogen) was incubated with 10 10
6 platelet MPs or added to
10ml of RA SF in a final volume of 100ml for 48h at 48C. Their
associations were evaluated using Cell-Tracker fluorescence (for
platelet MPs) or anti-CD41-PE (for SF). To detect vimentin and
fibrinogen on surface of MPs, platelet MPs (20 10
6) and RA SF
(20ml) were pre-incubated with 20mg/ml of CD32a blocking Fab
fragment antibody for 15min to abrogate any risk of potential non-
specific binding of primary/secondary antibodies to platelet Fc
receptor. MPs were then incubated with 25mg/ml goat anti-fibrinogen
(Abcam) or 1:100 goat anti-human vimentin (Sigma–Aldrich, ON,
Canada) for 48h at 48C. Samples were washed, centrifuged and pellets
retrieved in 100ml of PBS. For flow cytometry detection, 6.25mgo f
DyLight 649-conjugated F(ab)0
2 anti-goat IgG (Jackson ImmunoRe-
search) and anti-CD41-PE were added.
In vitro citrullination
Platelet MPs were prepared as described above and citrullinated
in vitro by rabbit muscle peptidyl arginine deiminase (PAD, Sigma–
Aldrich). 350 10
6MPs were incubated with/without 3U of PAD for
18h as described (Kuhn et al, 2006). Samples were lysed in Laemmli
buffer and processed as described above. The PVDF membranes were
incubated 18h in 10% of SF diluted in TBS-Tween, washed and
treated with Peroxidase-AffiniPure Goat Anti-Human IgG (Jackson
ImmunoResearch).
IgG BioPlex
To isolate the IgG contained in CD41
þ mpICs, RA SF (300ml) were
incubated in presence of 1.2mg of anti-CD41-PE for 30min, then with
50ml anti-PE magnetic beads (Miltenyi Biotec (MACS), CA, USA) for
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to LS magnetic MACS columns, washed with 3ml PBS 3 times and
eluted with 4.5ml PBS. The eluted CD41
þ MPs were centrifuged at
18,000g for 90min at 188C and pellets retrieved in 100ml of PBS
containing 0.5% Triton X-100 and 0.5% NP40. The CD41
þ MP lysates
were applied to a G-protein column, washed with 7ml PBS, then with
2ml PBS pH 5.0 and the IgG eluted with 100mM glycine pH 2.5.
The pH of the fraction was adjusted to 7.4 and conserved at  808C.
The reactivity of the antibodies retrieved from the mpICs against forty
candidate RA autoantigens (see Supporting Information Table S1 for
detailed list) were determined using a custom Bio-Plex
TM bead-based
antigen array as previously described (Hueber et al, 2005; Monach
et al, 2009; Zhao et al, 2008). Candidate RA peptide antigens were
coupled to spectrally distinct beads using N-hydroxysuccinimide ester
chemistry. Peptides were synthesized with a C-terminal biotin and
coupled to streptavidin-coated beads. The beads were pooled and
incubated with mpICs-derived IgG at RT. The remainder of the assay
was performed as previously described (Sokolove et al, 2012) and the
scores calculated. For comparison, a negative control where the
synovial fluid was incubated with an isotypic antibody was included.
Proteins were considered positive if the average fluorescence intensity
of the RA MPs was greater than twice that of the control. Results were
displayed in Java TreeView
1 (Version 1.1.3; Eisen et al, 1998).
Cryo-TEM and gold labelling of mpICs from RA SF
For cryo-Transmission Electron Microscopy (TEM) experiments, sam-
ples were diluted 10  in a buffer containing 150mM NaCl, 2mM
CaCl2 and 10mM HEPES, pH 7.4. A 10ml aliquot of SF was mixed with
1ml of 10nm Protein A-conjugated gold nanoparticles (Ted Pella, Inc.;
0.5mg/ml final concentration), incubated for 30min, mixed with 1ml
of 4nm Annexin-V-conjugated gold nanoparticles suspension
(1.4 10
15 particles/L final concentration) and further incubated for
15min. Aliquots (4ml) were deposited on TEM grids coated with a
perforated carbon film and quickly frozen in liquid ethane. TEM grids
were mounted on a Gatan 626 cryoholder and transferred into
a Tecnai F20 (FEI) microscope operated at 200kV. Images were
recorded with an USC1000-SSCCD camera (Gatan). The synthesis and
characterization of Annexin-V-conjugated gold nanoparticles will be
presented elsewhere (patent application Mornet and Brisson
WO2007122259).
Identification of autoantigens expressed by platelet MPs
from RA SF
We used mass spectrometry to survey the presence of known
autoantigens in platelet MPs in RA SF (see Supporting Information
Table S2 for detailed list). Protein concentration from individual SF
CD41
þ MPs (isolated using MACS as described above) was measured
using Dc Protein Assay (Bio-Rad, Hercules, CA).Twenty-five micrograms
proteins from individual SF CD41
þ MP sample were reduced and
alkylated by using 21mM triethyl phosphine (TEP) and 58mM
iodoethanol (IE). The samples were speed dried in a high speed
vacuum centrifuge and redissolved in 100ml of 0.1M ABC buffer
containing 0.1% perflurooctanoic acid (PFOA). Trypsin was added in
the ratio of 1mg per 50mg of proteins. The samples were placed in a
378C water bath for 16h. The reaction was stopped by drying the
samples and adding 70% IPA in ammonium hydroxide (50mM)
solution, pH 10. The enzyme was inactivated by reducing (TEP/
acetonitrile) at 458C for 1h and then alkylating (iodoethanol/CH3CN)
in the dark at 458C for 2h. A 1:1:1 solution of ethanol, ethyl acetate
and HPLC grade water with 0.1% TFA was added to the dried peptide
digest and subjected to high speed vacuum centrifuge to remove
PFOA.The samples were then analysed by LC–MS/MS. A total of four SF
biological replicates were analysed by mass spectrometry. PFOA was
purchased from TCI America (Portland, OR, USA). All other reagents
were of the highest quality commercially available.
Mass spectrometry and data analysis
The protein digests were analysed by LC–MS/MS using an Ultimate
3000 LC system (Dionex, San Francisco, CA) interfaced to an LTQ-
Orbitrap XL mass spectrometer (Thermo-Finnigan, Bremen, Germany).
The platform operated in the nano-LC mode using the standard nano-
ESI API stack fitted with a picotip emitter (uncoated fitting, 10mm
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The paper explained
PROBLEM:
Immune complexes (ICs) are formed after antibody deposition
against antigens and propagate inflammation in autoantibody-
driven autoimmune diseases. Extracellular vesicles of submicron
dimensions, called microparticles, are also often present in
the same pathologies where ICs are observed. Understanding
how ICs continuously form is of high relevance to human
diseases.
RESULTS:
We used a new generation of flow cytometer and sophisticated
cryo-transmission electron microscopy approaches to charac-
terize and quantify ICs and microparticles in the synovial fluid
from patients affected with rheumatoid arthritis (RA). We
identify a new class of ICs that predominates in RA; the
microparticle-associatedimmunecomplexes(mpICs).Wefurther
revealthatplateletmicroparticles participatetotheformationof
mpICs via exposure of the canonical RA autoantigens. We
demonstrate that these platelet mpICs are highly active, eliciting
pro-inflammatory leukotriene release by neutrophils.
IMPACT:
Considering the abundance of platelet microparticles in auto-
immune disease such as RA, this suggests that microparticles
may serve to the constant autoantibody deposition and
perpetuation of inflammation in chronic autoimmune
inflammatory disorders.
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through the column was maintained at 300nl/min using a 1:1000
splitter system. The protein digests (5ml) were injected into a reverse-
phase C18 PepMap trapping column (0.3 5mm
2,5mm particle size,
Dionex, Inc.) equilibrated with 0.1% formic acid/2% acetonitrile v/v
and washed for 5min with the equilibration solvent at a flow rate of
25ml/min, using an isocratic loading pump operated through an auto-
sampler. After the washing step, the trapping column was switched in-
line with a reversed-phase C18 Acclaim PepMap 100 column
(0.075 150mm
2, Dionex, Inc.) and the peptides were chromato-
graphed using a linear gradient of acetonitrile from 4.8 to 40% in
aqueous 0.1% formic acid over a period of 96min at the above-
mentioned flow rate such that the eluate was directly introduced to
the mass spectrometer. An 80% acetonitrile elution step was
subsequently performed for 5min prior to resetting the analytical
column to the initial equilibration conditions for 11 additional
minutes at the end of the chromatographic run. The mass spectro-
meter was operated in a data-dependent MS to MS/MS switching
mode, with the five most intense ions in each MS scan subjected to
MS/MS analysis. The full scan was performed at 60,000 resolution in
the Orbitrap detector and the MS/MS fragmentation scans were
performed in the ion trap detector (IT) CID mode such that the total
scan cycle frequency was approximately 1s.The threshold intensity for
the MS/MS trigger was always set at 1000 and the fragmentation was
carried out using the CID mode using normalized collision energy
(NCE) of 35. The data was collected in the profile mode for the full
scan and centroid mode for the MS/MS scans. The dynamic exclusion
function for previously selected precursor ions was enabled during the
analysis such that the following parameters were applied: repeat
count of 2, repeat duration of 45s, exclusion duration of 60s and
exclusion size list of 150. Xcalibur software (version 2.0.7), Thermo-
Finnigan, Inc., San Jose, CA) was used for instrument control, data
acquisition, and data processing. MS raw data files were searched
against Swiss-Prot (version 57) database using Mascot database
search software (version 2.1.04, Matrix Science, London, UK) to
identify peptides/proteins with the following parameters: S-hydro-
xyethylation of cysteine as a fixed modification, and oxidation of
methionine to methionine sulfoxide as variable modifications. The
mass tolerance for the precursor ion was set to 10ppm, and for the
product ion it was set to 0.8Da. Strict trypsin specificity was applied,
allowing for one missed cleavage. Peptides with a minimum score of
20 were considered as significant.
Isolation and stimulation of neutrophil and leukotriene
biosynthesis
Human neutrophils isolation and leukotriene quantifications were
determined as described (Boyum, 1968; Flamand et al, 2002).
Neutrophils were incubated at 378C for 30min in presence of RA SF
mpICs, platelet MPs (1 10
9MPs/ml), anti-fibrinogen (50mg/ml), or
in vitro mpICs. RA SF mpICs were enriched by centrifugations of
100ml of RA SF (18,000g for 90min at 188C) and resuspended in
10ml of PBS. In vitro mpICs were generated by pre-incubation of MPs
(1 10
9/ml) and goat anti-fibrinogen from Abcam (50mg/ml) at RT for
30min. Reactions were stopped by addition of 500ml cold methanol/
acetonitrile (1:1) containing 12.5ng of internal standards PGB2 and
19-OH-PGB2. Samples were stored at  208C O/N then analysed by
reverse-phase HPLC as previously described (Borgeat et al, 1990).
Statistical analysis
Statistical significance was determined using non-parametric Mann-
Whitney test. When indicated, unpaired Student’s t-test was
employed. All the statistical analyses were done using Prism software
package 4.00 (GraphPad Software, CA, USA).
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